Briacell Therapeutics Corp (BCT.TO) has had a mixed week, with a slight uptick on Friday amid broader market challenges.
This week, Briacell's stock fluctuated, closing at C$5.92 on Friday, down 1.39% for the week. However, it has shown some resilience, gaining nearly 6% over the past month. Let’s look at the latest price action, technical indicators, and relevant company news.
Advertisement
Briacell Therapeutics Corp
BCT.TO
BCT.TO
Briacell Therapeutics Corp
WealthAwesomeMarket cap
$43.32M
52W high
$20.40
52W low
$3.68
1W change
-1.39%
Beta
1.53
Analyst Price Targets
Based on analyst covering BCT · as of Sep 17, 2026
Wall Street analysts forecast BCT stock price to rise 301.6% over the next 12 months.
Consensus
BullishBased on avg. target vs last close (formal rating unavailable for Canadian listings)
Avg. Target
C$20.00
+301.6% Upside
Current Price
C$4.98
Last close
Targets are snapshotted when they change. Unchanged figures keep their original date. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on BCT's historical volatility
30-Day Vol
78.1%
Annualized
90-Day Vol
87.1%
Annualized
Trend (90d)
+50.0%
Annualized drift
90d Mean
C$5.95
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$5.29 | C$4.04 – C$6.92 |
| 60 trading days | C$5.61 | C$3.83 – C$8.21 |
| 90 trading days | C$5.95 | C$3.73 – C$9.49 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Advertisement
Investor takeaway: Investors should keep an eye on Briacell’s developments in cancer treatment, particularly its personalized immunotherapy approaches, while also considering the technical indicators that suggest a mixed outlook.
Briacell's stock has a 52-week range of C$3.68 to C$20.40, indicating significant volatility.
Currently, Briacell's stock is trading at about 13% of its 52-week range, highlighting both the potential for recovery and the risks tied to its recent performance.
Bull case
The positive sentiment around Briacell is driven by encouraging clinical results showing that its Bria-OTS™ immunotherapy can completely resolve lung metastasis in patients. Moreover, the average analyst target of C$20.00 suggests significant upside potential.
Bear case
On the flip side, the stock has faced challenges, with a year-to-date decline of 49.29%. Its fundamentals raise concerns, as it shows negative profitability metrics, including a profit margin of 0% and a return on equity of -175.3%. These factors cast doubt on the company's financial health and sustainability.
Latest Price Action
Advertisement
Briacell closed at C$5.92 on Friday, reflecting a 1.22% increase for the day. Despite this week's downturn, the stock has gained nearly 6% in the past month, indicating some recovery from earlier lows.
Technical Picture
Currently, Briacell's stock is trading about 17% above its 50-day moving average of C$5.06, which may suggest a potential upward trend. However, it remains below its 200-day moving average of C$6.44, indicating longer-term bearish sentiment. The stock has a beta of 1.53, highlighting its volatility compared to the broader market. The latest trading volume of 53,158 shares is significantly higher than the 20-day average volume of 8,825 shares, suggesting increased interest in the stock.
Company News and Developments
While there were no major announcements from Briacell this week, recent reports highlight the company's ongoing advancements in cancer therapy. Notably, Briacell reported the sustained complete resolution of lung metastasis in a patient treated with its Bria-OTS™ immunotherapy. This positive result underscores the potential effectiveness of its treatments in the competitive oncology market.
Best next step
Keep exploring this topic
If you want to go deeper, these are the most useful follow-up pages and tools for this topic.
Broker comparison
Best trading platforms in Canada
Compare $0-commission brokers before you act on a ticker story.
Safe cash
Best GIC rates in Canada
If the story makes you want to de-risk, compare guaranteed rates next.
HISA roundup
Best high-interest savings accounts
Keep dry powder in a no-fee savings account instead of chequing.
TFSA room
Check TFSA contribution room
Shelter the next contribution before you buy.
Advertisement
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile →✅ Reviewed by Certified Financial Professionals
This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
⚠️ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
